157 related articles for article (PubMed ID: 8320025)
1. Tumor necrosis factor: status in reactions in leprosy before and after treatment.
Bhattacharya SN; Chattopadhaya D; Saha K
Int J Dermatol; 1993 Jun; 32(6):436-9. PubMed ID: 8320025
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states.
Sarno EN; Grau GE; Vieira LM; Nery JA
Clin Exp Immunol; 1991 Apr; 84(1):103-8. PubMed ID: 2015700
[TBL] [Abstract][Full Text] [Related]
3. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
[TBL] [Abstract][Full Text] [Related]
4. Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage.
Naafs B
Int J Lepr Other Mycobact Dis; 1996 Dec; 64(4 Suppl):S21-8. PubMed ID: 9030120
[No Abstract] [Full Text] [Related]
5. IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment.
Partida-Sanchez S; Favila-Castillo L; Pedraza-Sanchez S; Gomez-Melgar M; Saul A; Estrada-Parra S; Estrada-Garcia I
Int Arch Allergy Immunol; 1998 May; 116(1):60-6. PubMed ID: 9623511
[TBL] [Abstract][Full Text] [Related]
6. Serum tumor necrosis factor and interleukin 1 in leprosy and during lepra reactions.
Parida SK; Grau GE; Zaheer SA; Mukherjee R
Clin Immunol Immunopathol; 1992 Apr; 63(1):23-7. PubMed ID: 1591878
[TBL] [Abstract][Full Text] [Related]
7. Levels of IgG subclasses in active and inactive cases in the disease spectrum of leprosy.
Beuria MK; Parkash O; Joshi B; Mohanty KK; Katoch K; Sengupta U
Int Arch Allergy Immunol; 1998 Jan; 115(1):61-6. PubMed ID: 9430497
[TBL] [Abstract][Full Text] [Related]
8. Serum zinc/copper ratio in subtypes of leprosy and effect of oral zinc therapy on reactional states.
George J; Bhatia VN; Balakrishnan S; Ramu G
Int J Lepr Other Mycobact Dis; 1991 Mar; 59(1):20-4. PubMed ID: 2030313
[TBL] [Abstract][Full Text] [Related]
9. Low serum HDL-cholesterol is associated with raised tumor necrosis factor-alpha during ENL reactions.
Memon RA; Kifayet A; Shahid F; Lateef A; Chiang J; Hussain R
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):1-11. PubMed ID: 9207748
[TBL] [Abstract][Full Text] [Related]
10. Reaction in leprosy: acute phase reactant response during and after remission.
Sehgal VN; Bhattacharya SN; Shah Y; Sharma VK; Gupta CK
Int J Dermatol; 1992 Sep; 31(9):632-4. PubMed ID: 1459760
[TBL] [Abstract][Full Text] [Related]
11. Determination of circulating IgG subclasses against lipoarabinomannan in the leprosy spectrum and reactions.
Beuria MK; Mohanty KK; Katoch K; Sengupta U
Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):422-8. PubMed ID: 10700917
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 open trial of pentoxifylline for the treatment of leprosy reactions.
Dawlah ZM; Cabrera A; Ahern K; Levis WR
Int J Lepr Other Mycobact Dis; 2002 Mar; 70(1):38-43. PubMed ID: 12120041
[No Abstract] [Full Text] [Related]
13. Cytokines in leprosy, II. Effect of treatment on serum cytokines in leprosy.
Moubasher AD; Kamel NA; Zedan H; Raheem DD
Int J Dermatol; 1998 Oct; 37(10):741-6. PubMed ID: 9802683
[TBL] [Abstract][Full Text] [Related]
14. Leprosy reactions in postelimination stage: the Bangladesh experience.
Mowla MR; Ara S; Mizanur Rahman AFM; Tripura SP; Paul S
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):705-711. PubMed ID: 27859670
[TBL] [Abstract][Full Text] [Related]
15. Delayed-type hypersensitivity reactions followed by erythema nodosum leprosum.
Rea TH; Sieling PA
Int J Lepr Other Mycobact Dis; 1998 Sep; 66(3):316-27. PubMed ID: 9934358
[TBL] [Abstract][Full Text] [Related]
16. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
Becx-Bleumink M; Berhe D
Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):173-84. PubMed ID: 1522359
[TBL] [Abstract][Full Text] [Related]
17. Necrotic erythema nodosum leprosum with oral mucosal involvement.
Swain JP; Soud A; Agarwal SK
Indian J Lepr; 2008; 80(2):175-8. PubMed ID: 19425513
[TBL] [Abstract][Full Text] [Related]
18. Erythema nodosum leprosum necroticans in a child--an unusual manifestation.
Pandhi D; Mehta S; Agrawal S; Singal A
Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):122-6. PubMed ID: 16830655
[TBL] [Abstract][Full Text] [Related]
19. Effect of rhuIFN-gamma treatment in multibacillary leprosy patients.
Sampaio EP; Malta AM; Sarno EN; Kaplan G
Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):268-73. PubMed ID: 8862260
[TBL] [Abstract][Full Text] [Related]
20. Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL).
Sampaio EP; Moraes MO; Nery JA; Santos AR; Matos HC; Sarno EN
Clin Exp Immunol; 1998 Feb; 111(2):300-8. PubMed ID: 9486396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
